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Purpose: Neutrophil-to-lymphocyte ratio (NLR) was evaluated as a prognostic factor in patients with metastatic
clear cell renal cell carcinoma (RCC) receiving sunitinib as first line therapy.
Methods: Between December 2005 and December 2011, 109 patients with metastatic clear cell RCC were treated
with sunitinib. The values of NLR were assessed at two time points: at baseline (pre-treatment) and on day 1 of
the second cycle (post-treatment). The prognostic significance of NLR on treatment outcome was evaluated with
adjustment for known confounding risk factors.
Results: The median follow-up duration after sunitinib treatment was 24 months. There was no association
between the pre-treatment NLR and tumor response (median pre-treatment NLRs: 2.2 for partial response [PR],
2.3 for stable disease [SD], and 1.9 for progressive disease [PD]; p = 0.531). However, lower post-treatment NLR
(1.1 for PR, 1.2 for SD, 2.3 for PD; p = 0.021) and larger reduction in NLR after treatment (-45.8% for PR, -45.6% for
SD, 14.8% for PD; p = 0.009) was significantly associated with a better tumor response. When the patients were
divided into two subgroups according to the cutoff value of the post-treatment NLR 1.1, the differences in median
cancer-specific survival were observed between subgroups (not reached vs. 19.0 months, p = 0.012). In multivariate
analysis, body mass index, MSKCC risk group, serum hemoglobin, and post-treatment NLR were significantly
associated with cancer-specific mortality.
Conclusions: Higher post-treatment NLR was associated with poor prognosis. An early reduction in the NLR
after sunitinib treatment may indicate survival benefit in patients with metastatic clear cell RCC.
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Inflammation plays a critical role in many aspects of
cancer, including cancer development, growth, and pro-
gression (Mantovani et al. 2008). It is now established that
progression of cancer is not only determined by the tumor
characteristics but also by the host response. Several stud-
ies recently revealed that systemic inflammatory markers
were associated with poorer prognosis in cancer patients
(Vakkila and Lotze 2004; McMillan 2008). In patients with* Correspondence: hhkim@snu.ac.kr
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in any medium, provided the original work is prenal cell carcinoma (RCC), serum C-reactive protein
(CRP) level (Steffens et al. 2012; Yasuda et al. 2012; Saito
and Kihara 2010) and the Glasgow Prognostic Score
(Ramsey et al. 2007; Lamb et al. 2012) have prognostic
significance.
The relative difference in the neutrophil and lympho-
cyte counts, the neutrophil-to-lymphocyte ratio (NLR),
has attracted the interests of investigators as an emer-
ging systemic inflammatory marker. A high preoperative
or pre-treatment NLR was identified as an independent
prognostic factor associated with poor survival in various
cancers, including breast cancer, colon cancer, gastric
cancer, and meshothelioma (Azab et al. 2012; Chua et al.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Baseline patient characteristics
Factors Distribution




BMI (kg/m2)* 23.3, 23.2 (21.4 ~ 25.1)








Synchronous metastasis (%) 56 (51.4)
Multiple organ metastasis (%) 52 (47.7)
Hemoglobin (g/dℓ)* 12.7, 12.8 (11.6 ~ 13.9)
Albumin (g/dℓ)* 4.1, 4.2 (3.9 ~ 4.4))
Corrected calcium (mg/dℓ)* 9.5, 9.3 (9.0 ~ 9.6)
Pre-treatment NLR* 2.8, 2.3 (1.5 ~ 3.1)
Post-treatment NLR* 1.4, 1.2 (0.8 ~ 1.7)
*Values are expressed as mean, median (interquartile range).
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patients with RCC found that an increased preoperative
or pre-treatment NLR was associated with poor prognosis
(Cetin et al. 2013; Ohno et al. 2010, 2012; Keizman et al.
2012). However, to the best of our knowledge, the asso-
ciation between the NLRs at different time points and
treatment outcome in metastatic RCC patients receiving
sunitinib has not been previously reported. In this study,
we evaluated whether the NLR can be used as a surrogate
indicator of treatment efficacy and prognosis in patients
with metastatic clear cell RCC receiving sunitinib as first
line therapy.
Materials and methods
Between December 2005 and December 2011, 113 pa-
tients with histologically confirmed metastatic clear cell
RCC were treated with sunitinib as first line therapy. We
excluded four patients who did not undergo radical or
partial nephrectomy for a primary lesion. Thus, 109 pa-
tients who underwent curative surgery for a primary le-
sion were included in this study: radical nephrectomy in
87 patients (79.8%) and partial nephrectomy in 22
(20.2%). The tumor stage was determined according to
the 7th TNM classification of the Union Internationale
Centre le Cancer (UICC) and the American Joint Com-
mittee on Cancer (AJCC) guidelines (Edge and Compton
2010) and grades of tumor were determined according
to the Fuhrman’s grading system (Fuhrman et al. 1982).
Sunitinib was administered orally at a dose of 50 mg
once daily in 6-week cycles consisting of a 4-week on
and 2-week off schedule (Motzer et al. 2007). For pa-
tients who developed toxicity, doses were reduced in sin-
gle decrements of 12.5 mg to a minimum dose of 25 mg
daily. After approval by the Institutional Review Board
at Seoul National University Hospital, we reviewed the
patient clinical data for gender, age, body mass index
(BMI), ECOG performance status, pre-treatment la-
boratory findings, and treatment outcomes. The NLR
was calculated by dividing the neutrophil count by the
lymphocyte count. The values of NLR were assessed at
two time points: just before the first cycle (pre-treatment)
and on day 1 of the second cycle (post-treatment).
Tumor response was assessed every three cycles with
computed tomography, based on the Response Evaluation
Criteria In Solid Tumors (RECIST) criteria (Eisenhauer
et al. 2009) using laboratory tests, chest X-ray, and abdo-
minal CT scans. Cancer-specific death was attributed to
patients with evidence of cancer progression before death
by reviewing the patient’s medical records and/or the
following codes using the International Classification of
Diseases 10th revisions (ICD-10 code C64) from the data-
base of the Korea National Statistical Office.
All statistical analysis was performed using IBM SPSS
software, version 19.0 (SPSS, Inc., an IBM Company,Chicago, Illinois, USA). Data were summarized with the
number of subjects and the mean or median value.
Demographics and clinical parameters were analyzed
with the chi-square test for categorical variables and
with the Mann–Whitney U test or the Kruskal–Wallis
test, as appropriate for continuous variables. A receiver
operating characteristics (ROC) curve was constructed
to estimate the optimal cut-off value of NLR. The
cancer-specific survival rates were estimated using the
Kaplan-Meier method and compared using the log rank
test. A multivariate analysis was performed by Cox pro-
portional hazard regression model for variables signifi-
cant on univariate analysis. Two-sided null hypotheses
of no difference were rejected if p-values were less than
0.05, or, equivalently, if the 95% confidence interval (CI)
of hazard ratio estimates excluded 1.
Results
Baseline characteristics and treatment outcomes
Pre-treatment and post-treatment NLRs were available
in all patients. Table 1 shows the baseline characteristics
of the entire study population. The median follow-up
duration after sunitinib treatment was 24 (interquartile
range [IQR] 10–35) months. Objective response after
3 cycles of sunitinib treatment was complete response
(CR) 0% (n = 0), partial response (PR) 45.0% (n = 49),
stable disease (SD) 34.9% (n = 38), and progressive disease
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for the entire group was 26.0 (95% CI 16.7 ~ 35.3) months.
Analysis for pre-treatment and post-treatment NLRs
The pre-treatment NLR ranged from 0.63 to 28.61, with
a median value of 2.27 and a mean value of 2.82. There
were no differences in the pre-treatment NLR by the
patients’ characteristics, including age, gender, BMI, and
ECOG performance status. There was no association
between the pre-treatment NLR and the tumor response
(median pre-treatment NLRs: 2.2 for PR, 2.3 for SD, and
1.9 for PD; p = 0.531) (Figure 1).
Across all study subjects, a 32.6% reduction in the me-
dian proportion of neutrophils (p < 0.001), a 5.6% increase
in the median proportion of lymphocyte (p < 0.001), and a
38.3% reduction in the median post-treatment NLR oc-
curred after first cycle of sunitinib treatment. The post-
treatment NLR ranged from 0.24 to 5.42, with a median
value of 1.18 and a mean value of 1.44. Better tumor
response was significantly associated with the lower
post-treatment NLR (1.1 for PR, 1.2 for SD, 2.3 for
PD; p = 0.021) and the larger reduction in NLR after
first cycle of sunitinib treatment (-45.8% for PR, -45.6%
for SD, 14.8% for PD; p = 0.009) (Figure 1).
Pre-treatment and post-treatment NLRs and survival
outcomes
The patients were divided into two subgroups according
to the cutoff value of the pre-treatment NLR 2.5, and
post-treatment NLR 1.1 using receiver operating charac-
teristics curve analysis. The differences in the cancer-
specific survival according to the pre-treatment and
post-treatment NLRs are presented in Figure 2. Kaplan–
Meier univariate analysis showed significantly shorter
median cancer-specific survival in patients with: (a) higherFigure 1 Box plots showing distributions of NLR values according to
(3) % Changes in post-treatment NLR.pre-treatment NLR (36.0 [95% CI 23.3 ~ 48.7] vs. 17.0
[95% CI 12.9 ~ 21.1] months, p = 0.014); and (b) higher
post-treatment NLR (not reached vs. 19.0 [14.6 ~ 23.4]
months, p = 0.012).On univariate analysis, BMI, MSKCC
risk group, synchronous metastasis, multiple organ metas-
tasis, serum hemoglobin, albumin, corrected calcium level,
pre-treatment NLR, and post-treatment NLR were signifi-
cantly associated with cancer-specific survival and multi-
variate analysis retained BMI, MSKCC risk group, serum
hemoglobin level, and post-treatment NLR as independ-
ent predictive factors for cancer-specific survival (Table 2).
Discussion
Prediction of tumor response is a critical issue in the
treatment of metastatic cancer. However, only a few arti-
cles investigated the NLR as a potential prognostic factor
in patients with metastatic RCC undergoing targeted
therapy (Cetin et al. 2013; Keizman et al. 2012). The
present study focused on the predictive value of the NLR
in the outcome of patients with metastatic clear cell RCC
receiving sunitinib as first line therapy. We found that a
significant reduction in the NLR after sunitinib treatment,
resulting from a reduction in neutrophils, and an increase
in lymphocytes, is associated with a better tumor response
and a longer cancer-specific survival in patients with me-
tastatic clear cell RCC.
It has become clear that cancer progression is depen-
dent on a complex interaction between the tumor and the
host inflammatory response (Vakkila and Lotze 2004).
Several lines of evidence demonstrated that RCC is related
with inflammatory response. Wu et al. undertook a sys-
tematic meta-analysis to predict a role of systemic inflam-
matory response for survival in RCC (Wu et al. 2011).
Three inflammatory markers were significantly associated
with cancer-specific survival, with the pooled hazard ratiothe tumor response. (1) Pre-treatment NLR. (2) Post-treatment NLR.
Figure 2 Cancer-specific survival of the patients stratified by the pre-treatment and post-treatment NLR. (1) By the cut-off point 2.5 of
pre-treatment NLR. (2) By the cut-off point 1.1 of post-treatment NLR.
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Table 2 Prognostic factors associated with poor cancer-specific survival
Factors Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age (cont.) 1.004 0.980 ~ 1.028 0.762 - - -
Gender (%)
Male Reference - - -
Female 1.087 0.574 ~ 2.059 0.797 - - -
BMI (kg/m2) (cont.) 0.891 0.812 ~ 0.979 0.016 0.884 0.668 ~ 0.924 0.031
ECOG performance status (%)
0 Reference - - -
1 1.576 0.907 ~ 2.807 0.105 - - -
2 1.598 0.879 ~ 5.131 0.457 - - -
MSKCC risk group (%)
Good Reference Reference
Intermediate 2.743 1.444 ~ 5.212 0.002 2.841 1.191 ~ 6.777 0.019
Poor 10.155 2.168 ~ 47.569 0.003 7.503 1.282 ~ 40.904 0.025
Synchronous metastasis (%) 1.855 1.093 ~ 3.146 0.022 1.598 0.783 ~ 3.260 0.197
Multiple organ metastasis (%) 1.769 1.033 ~ 3.029 0.038 1.237 0.624 ~ 1.736 0.789
Hemoglobin (g/dℓ) < reference value 0.672 0.565 ~ 0.800 0.001 0.756 0.595 ~ 0.959 0.021
Albumin≥ 3.5 g/dℓ 0.442 0.262 ~ 0.744 0.002 1.000 0.493 ~ 2.028 1.000
Corrected calcium≥ 10.0 mg/dℓ 1.352 1.090 ~ 1.677 0.006 1.132 0.876 ~ 1.462 0.345
Pre-treatment NLR≤ 2.5 1.237 1.012 ~ 1.568 0.021 1.023 0.864 ~ 1.157 0.542
Post-treatment NLR≤ 1.1 1.943 1.125 ~ 3.747 0.017 2.127 1.021 ~ 4.535 0.038
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(95% CI 2.25 ~ 4.62) for thrombocytosis, and 3.85 (95%
CI 3.31 ~ 4.48) for elevated erythrocyte sedimentation rate
(ESR). Therefore, strategies which reflect the host inflam-
matory response are promising prognostic factors.
Accumulated evidence has demonstrated that an ele-
vated NLR represents a significant prognostic factor of
poor clinical outcome in different types of cancer (Azab
et al. 2012; Chua et al. 2011; Kao et al. 2010; Keizman
et al. 2012). In addition to being measured easily, NLR is
more valuable due to its special property as a combined
factor of inflammation and host immune reaction. Ohno
et al. first found NLR of value to predict recurrence in
patients with non-metastatic RCC (Ohno et al. 2010).
They reported that patients with NLR higher than 2.7
showed a significantly lower 5-year recurrence-free
survival rates compared to those with NLR less than
2.7 (77.9 vs. 93.8%, p = 0.0205). They also investigated
the clinical value of postoperative changes in NLR in
patients with non-metastatic RCC; NLR significantly
decreased after curative surgery, and increased at re-
currence of RCC (Ohno et al. 2012). The magnitude
of NLR changes after treatment may correlate with
the bulk of disease. In our study, we can replicate this
finding; changes in NLR after sunitinib treatment were
correlated with the tumor response.In patients treated with tyrosine kinase inhibitors for
metastatic RCC, patients with higher pre-treatment
NLR had poorer prognosis than those with lower pre-
treatment NLR (Cetin et al. 2013; Keizman et al. 2012).
These findings are consistent with our study. However, be-
cause the pre-treatment NLR might be highly correlated
with the post-treatment NLR, we should clarify the roles
of each NLR values in determining the prognosis in
this study population. On multivariate analysis, the post-
treatment NLR was a significant predictor of cancer-
specific survival, thus, the strength of prediction seems to
be greater in the post-treatment NLR that can also reflect
the efficacy of treatment. We believe that our study has an
advantage over prior studies due to the assessment of the
post-treatment NLR as a new prognostic marker after
sunitinib treatment.
It is unclear how elevated NLR would be responsible
for treatment outcome. Some studies list possible mecha-
nisms of NLR in cancer progression as follows: neutro-
phils, in response to IL-8 released by tumor cells, might
contribute to cancer growth and metastasis by producing
several cytokines (De Larco et al. 2004), and lymphocytes
might be responsible for an inadequate immunologic reac-
tion and, consequently, a weakened host defense against
cancer (Hoffmann et al. 2002). Thus, the NLR may incor-
porate prognostic information of these two important
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ment outcome than either alone.
The current study has several limitations. First, although
we tried to control possible factors which could influence
the results by multivariate analysis properly, it is a retro-
spective study with a small number of patients in a single
institution. Another potential limitation is that serum
NLR was not compared to the extent of inflammatory cell
infiltration within and surrounding the tumor. Such his-
tological correlations should be considered in future
analysis. However, despite these limitations, this study first
established the post-treatment NLR as a surrogate indica-
tor of treatment efficacy and prognosis in patients with
metastatic clear cell RCC receiving sunitinib as first line
therapy, which could help define the ideal patient popula-
tion for aggressive follow-up and treatment.
Conclusions
The present study shows that a significant reduction
in the NLR after sunitinib treatment, resulting from a
reduction in neutrophils, an increase in lymphocytes,
is associated with a better tumor response and a longer
cancer-specific survival in patients with metastatic clear
cell RCC receiving sunitinib as first line therapy. Fur-
ther studies are required to confirm a more detailed
clinical relevance and biological mechanisms of post-
treatment NLR.
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